A biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. The company's scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, with therapeutic candidates designed to provide benefits across autoimmune, neurodegenerative, and ophthalmic diseases. It has proof-of-concept data in Guillain-Barré syndrome, Huntington’s disease, and geographic atrophy, and is advancing mid-to-late-stage clinical trials.
